Press Releases
November 18, 2024
Sionna Therapeutics Announces Appointment of Laurie Stelzer to its Board of Directors
Read more
August 13, 2024
Sionna Therapeutics Announces Initiation of Two Phase 1 Clinical Trials of SION-719 and SION-451, in Development for Cystic Fibrosis
Read more
July 16, 2024
Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie
Read more
June 3, 2024
Sionna Therapeutics Announces Appointment of Jennifer Fitzpatrick as General Counsel
Read more
March 6, 2024
Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis
Read more
January 24, 2024
Sionna Therapeutics Announces Phase 1 Initiation for SION-109 in Cystic Fibrosis
Read more
January 3, 2024
Sionna Therapeutics to Present Updates on Clinical Progress in Cystic Fibrosis at 42nd Annual J.P. Morgan Healthcare Conference
Read more
November 3, 2023
Sionna Therapeutics Presents Preclinical Data at 2023 North American Cystic Fibrosis Conference Demonstrating Series 2 NBD1 Stabilizers Normalize ΔF508-CFTR Function
Read more
October 18, 2023
Sionna Therapeutics to Present at 2023 North American Cystic Fibrosis Conference
Read more
June 8, 2023
Sionna Therapeutics Announces Presentation of Preclinical Data on NBD1 Stabilizers at 46th European Cystic Fibrosis Conference
Read more
January 5, 2023
Sionna Therapeutics Announces Advancement of Cystic Fibrosis Pipeline Programs and Presentation at J.P. Morgan 41st Annual Healthcare Conference
Read more
December 7, 2022
Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis
Read more
November 14, 2022
Sionna Therapeutics Announces Appointment of Vanya Sagar as Chief People Officer
Read more
November 3, 2022
Sionna Therapeutics Presents Preclinical Data Demonstrating Restoration of ΔF508-CFTR by Stabilizing NBD1 with SION-638 in Cystic Fibrosis
Read more
October 4, 2022
Sionna Therapeutics to Present at the North American Cystic Fibrosis Conference
Read more
June 6, 2022
Sionna Therapeutics Announces Appointment of Paul Clancy to Board of Directors
Read more
April 19, 2022
Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis
Read more
Our Corporate Presentations & Events
There are no upcoming events scheduled at this time.